| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,784 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,025 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Duraibabu Prathyusha |
Vice President, Finance |
• – – |
2022-04-25 |
4 |
D |
$4.83 |
$3,197 |
D/D |
(662) |
86,772 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2022-04-25 |
4 |
D |
$4.83 |
$3,990 |
D/D |
(826) |
103,167 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2022-04-24 |
4 |
D |
$4.70 |
$18,687 |
D/D |
(3,976) |
90,849 |
|
- |
|
| Duraibabu Prathyusha |
Vice President, Finance |
• – – |
2022-03-25 |
4 |
D |
$5.75 |
$1,984 |
D/D |
(345) |
87,434 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
41,000 |
94,825 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2022-02-25 |
4 |
D |
$5.90 |
$9,239 |
D/D |
(1,566) |
53,825 |
|
- |
|
| Duraibabu Prathyusha |
Vice President, Finance |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
41,000 |
87,779 |
|
- |
|
| Duraibabu Prathyusha |
Vice President, Finance |
• – – |
2022-02-25 |
4 |
D |
$5.90 |
$20,497 |
D/D |
(3,474) |
46,779 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
59,400 |
184,984 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2022-02-25 |
4 |
D |
$5.90 |
$27,199 |
D/D |
(4,610) |
125,584 |
|
- |
|
| Meyers James R |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
35,700 |
|
- |
|
| Markels John |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
25,700 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
45,100 |
103,993 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2022-02-25 |
4 |
D |
$5.90 |
$36,863 |
D/D |
(6,248) |
58,893 |
|
- |
|
| Hillan Kenneth |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
35,700 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
35,700 |
|
- |
|
| Schott Robert J. |
SVP, Head of Development |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
41,000 |
75,537 |
|
- |
|
| Smith Karen L. |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
38,200 |
|
- |
|
| Parker H Stewart |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
43,700 |
|
- |
|
| Carey Robert |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
35,700 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
54,000 |
142,429 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2022-02-25 |
4 |
D |
$5.90 |
$73,089 |
D/D |
(12,388) |
88,429 |
|
- |
|
| Macrae Sandy |
President, CEO and Director |
• • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
224,000 |
521,176 |
|
- |
|
| Macrae Sandy |
President, CEO and Director |
• • – |
2022-02-25 |
4 |
D |
$5.90 |
$294,351 |
D/D |
(49,890) |
297,176 |
|
- |
|
| Zakrzewski Joseph S |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
60,700 |
|
- |
|
1096 Records found
|
|
Page 4 of 44 |
|
|
0.04 (6.83%) 
